Resistance to anti-HER2 therapy in HER2+ breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK Meeting Abstract


Authors: Smith, A. E.; Chandarlapaty, S.
Abstract Title: Resistance to anti-HER2 therapy in HER2+ breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK
Meeting Title: 111th Annual Meeting of the American Association for Cancer Research (AACR)
Journal Title: Cancer Research
Volume: 80
Issue: 16 Suppl.
Meeting Dates: 2020 Apr 27-28/Jun 22-24
Meeting Location: Philadelphia, PA
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2020-08-01
Language: English
ACCESSION: WOS:000590059304151
DOI: 10.1158/1538-7445.Am2020-1910
PROVIDER: wos
Notes: Meeting Abstract: 1910 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Alison Elizabeth Smith
    3 Smith